Do Common Infections Cause Stroke?

ABSTRACT

Infections have long been recognized as a potential, if uncommon, cause of cerebrovascular disease. In recent years, with the growing recognition of the importance of inflammation in atherosclerosis, there has been renewed interest in the possibility that common infections may participate in the atherosclerotic process or lead to stroke through other mechanisms. Specific organisms that have been implicated include Chlamydia pneumoniae, herpes viruses, human immunodeficiency virus, Helicobacter pylori, and organisms associated with periodontal infections. This article outlines the epidemiological, pathological, and laboratory evidence that these infections may be associated with atherosclerosis and stroke. Although definitive proof of an association between a specific infection and stroke is generally lacking, the accumulating evidence does indicate that several types of infections may be among the modifiable risk factors that contribute to the risk of stroke.

Infection - stroke - risk factors - Chlamydia pneumoniae - human immunodeficiency virus

REFERENCES

• 1 Sacco R L. Risk factors, outcomes, and stroke subtypes for ischemic stroke.  Neurology. 1997;  49(suppl 4) S39-S44
• 2 Zhu J, Nieto F J, Horne B D, Anderson J L, Muhlestein J B, Epstein S E. Prospective study of pathogen burden and risk of myocardial infarction or death.  Circulation. 2001;  103 45-51
• 3 Espinola-Klein C, Rupprecht H J, Blankenberg S et al.. Impact of infectious burden on extent and long-term prognosis of atherosclerosis.  Circulation. 2002;  105 15-21
• 4 Bova I Y, Bornstein N M, Korczyn A D. Acute infection as a risk factor for ischemic stroke.  Stroke. 1996;  27 2204-2206
• 5 Grau A J, Buggle F, Becher H et al.. Recent bacterial and viral infection is a risk factor for cerebrovascular ischemia.  Neurology. 1998;  50 196-203
• 6 Grau A J, Buggle F, Ziegler C et al.. Association between acute cerebrovascular ischemia and chronic or recurrent infection.  Stroke. 1997;  28 1724-1729
• 7 Grau A J, Brandt T, Buggle F et al.. Association of cervical artery dissection with recent infection.  Arch Neurol. 1999;  56 851-856
• 8 Meier C R, Derby L E, Jick S S, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction.  JAMA. 1999;  281 427-431
• 9 Luchsinger J A, Pablos-Mendez A, Knirsch C, Rabinowitz D, Shea S. Antibiotic use and risk of ischemic stroke in the elderly.  Am J Med. 2001;  111 361-366
• 10 Grayston J T, Kuo C C, Wang S P, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.  N Engl J Med. 1986;  315 161-168
• 11 Kuo C C, Jackson L A, Campbell L A, Grayston J T. Chlamydia pneumoniae (TWAR).  Clin Microbiol Rev. 1995;  8 451-461
• 12 Chaim W, Sarov B, Sarov I, Piura B, Cohen A, Insler V. Serum IgG and IgA antibodies to chlamydia in ectopic pregnancies.  Contraception. 1989;  40 59-71
• 13 Kuo C C, Shor A, Campbell L A, Fukushi H, Patton D L, Grayston J T. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries.  J Infect Dis. 1993;  167 841-849
• 14 Ramirez J A. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis.  Ann Intern Med. 1996;  125 979-982
• 15 Grayston J T, Kuo C C, Coulson A S et al.. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.  Circulation. 1995;  92 3397-3400
• 16 Maass M, Bartels C, Engel P M, Mamat U, Sievers H H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease.  J Am Coll Cardiol. 1998;  31 827-832
• 17 Jackson L A, Campbell L A, Kuo C C, Rodriguez D I, Lee A, Grayston J T. Isolation of Chlamydia pneumoniae from a carotid artery specimen.  J Infect Dis. 1997;  176 292-295
• 18 Virok D, Kis Z, Karai L et al.. Chlamydia pneumoniae in atherosclerotic middle cerebral artery.  Stroke. 2001;  32 1973-1976
• 19 Vink A, Poppen M, Schoneveld A H et al.. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual.  Circulation. 2001;  103 1613-1617
• 20 Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?.  Lancet. 1997;  350 430-436
• 21 Gaydos C A, Summersgill J T, Sahney N N, Ramirez J A, Quinn T C. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells.  Infect Immun. 1996;  64 1614-1620
• 22 Kaukoranta-Tolvanen SSE, Teppo A M, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response.  Microb Pathog. 1996;  21 215-221
• 23 Nadareishvili Z G, Koziol D E, Szekely B et al.. Increased CD8+ T cells associated with Chlamydia pneumoniae in symptomatic carotid plaque.  Stroke. 2001;  32 1966-1972
• 24 Linnanmäki E, Leinonen M, Ekman M R et al.. Chlamydiae pneumoniae specific circulating immune complexes in chronic coronary heart disease.  Circulation. 1993;  87 1130-1134
• 25 Wimmer MLJ, Sandmann-Strupp R, Saikku P, Haberl R L. Association of chlamydial infection with cerebrovascular disease.  Stroke. 1996;  27 2207-2210
• 26 Kalayoglu M V, Byrne B I. Induction of macrophage foam cell formation by Chlamydia pneumoniae .  J Infect Dis. 1998;  177 725-729
• 27 Morrison R P, Belland R J, Lyng K, Caldwell H D. Chlamydial disease pathogenesis: the 57-kD chlamydial hypersensitivity antigen is a stress response protein.  J Exp Med. 1989;  170 1271-1283
• 28 Dahlén G H, Boman J, Birgander L S, Lindblom B. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease.  Atherosclerosis. 1995;  114 165-174
• 29 Kalayoglu M V, Libby P, Byrne G I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease.  JAMA. 2002;  288 2724-2731
• 30 Madre J G, Garcia J L, Gonzalez R C et al.. Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke.  Eur J Neurol. 2002;  9 303-306
• 31 Cook P J, Honeybourne D, Lip GYH, Beevers D G, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project.  Stroke. 1998;  29 404-410
• 32 Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease.  Stroke. 1999;  30 299-305
• 33 Glader C A, Stegmayr B, Boman J et al.. Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions.  Stroke. 1999;  30 2013-2018
• 34 Tanne D, Haim M, Boyko V et al.. Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke.  Cerebrovasc Dis. 2003;  16 166-170
• 35 Heuschmann P U, Neureiter D, Gesslein M et al.. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study.  Stroke. 2001;  32 2253-2258
• 36 Elkind M S, Lin I F, Grayston T J, Sacco R L. Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan Stroke Study.  Stroke. 2000;  31 1521-1525
• 37 Elkind M S, Sciacca R, Tondella MLC, Feikin D, Fields B, DiTullio M R. Antibodies to Chlamydia pneumoniae are associated with risk of ischemic stroke.  Neurology. 2003;  60(suppl 1) A256-A257
• 38 Von Hertzen L, Alakarppa H, Koskinen R et al.. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease.  Epidemiol Infect. 1997;  118 155-164
• 39 Chaim W, Sarov B, Sarov I, Piura B, Cohen A, Insler V. Serum IgG and IgA antibodies to chlamydia in ectopic pregnancies.  Contraception. 1989;  40 59-71
• 40 Minick C R, Fabricant C G, Fabricant J, Litrenta M M. Atheroarteriosclerosis induced by infection with a herpesvirus.  Am J Pathol. 1979;  96 673-706
• 41 Fabricant C G, Fabricant J, Minick C R, Litrenta M M. Herpesvirus-induced atherosclerosis in chickens.  Fed Proc. 1983;  42 2476-2479
• 42 Benditt E P, Barrett T, McDougall J K. Viruses in the etiology of atherosclerosis.  Proc Natl Acad Sci USA. 1983;  80 6386-6389
• 43 Ventura H O, Mehra M R, Smart F W, Stapleton D D. Cardiac allograft vasculopathy: current concepts.  Am Heart J. 1995;  129 791-798
• 44 Melnick J L, Adam E, Debakey M E. Possible role of cytomegalovirus in atherogenesis.  JAMA. 1990;  263 2204-2207
• 45 Espinola-Klein C, Rupprecht H-J, Blankenberg S et al.. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection?.  Stroke. 2000;  31 2127-2133
• 46 Sorlie P D, Nieto F J, Adam E, Folsom A R, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study.  Arch Intern Med. 2000;  160 2027-2032
• 47 Muhlestein J B, Horne B D, Carlquist J F et al.. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease.  Circulation. 2000;  102 1917-1923
• 48 Speir E, Modali R, Huang E S et al.. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.  Science. 1994;  265 391-394
• 49 Hendrix M G, Salimans M M, van Boven C P, Bruggeman C A. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis.  Am J Pathol. 1990;  136 23-28
• 50 Ridker P M, Hennekens C H, Stampfer M J et al.. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke.  Circulation. 1998;  98 2796-2799
• 51 Lemstrom K B, Aho P T, Bruggeman C A, Hayry P J. Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor-beta 1 in rat aortic allografts: possible mechanism for cytomegalovirus-enhanced graft arteriosclerosis.  Arterioscler Thromb. 1994;  14 2043-2052
• 52 Geist L J, Monick M M, Stinski M F, Hunninghake G W. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin 2 and interleukin 2 receptor genes.  Am J Respir Cell Mol Biol. 1991;  5 292-296
• 53 Geist L J, Monick M M, Stinski M F, Hunninghake G W. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-alpha gene expression.  J Clin Invest. 1994;  93 474-478
• 54 Kowalik T F, Wing B, Haskill J S, Azizkhan J C, Baldwin A S, Huang E S. Multiple mechanisms are implicated in the regulation of NF-B activity during human cytomegalovirus infection.  Proc Natl Acad Sci USA. 1993;  90 1107-1111
• 55 Yonemitsu Y, Kaneda Y, Komori K, Hirai K, Sugimachi K, Sueishi K. The immediate early gene of human cytomegalovirus stimulates vascular smooth muscle cell proliferation in vitro and in vivo.  Biochem Biophys Res Commun. 1997;  231 447-451
• 56 Pinto A N. AIDS and cerebrovascular disease.  Stroke. 1996;  27 538-545
• 57 Cole J W, Pinto A N, Hebel J R et al.. Acquired immunodeficiency syndrome and the risk of stroke.  Stroke. 2004;  35 51-56
• 58 Evers S, Nabavi D, Rahmann A, Heese C, Reichelt D, Husstedt I W. Ischemic cerebrovascular events in HIV infection.  Cerebrovasc Dis. 2003;  15 199-205
• 59 Shen Y M, Frenkel E P. Thrombosis and a hypercoagulable state in HIV-infected patients.  Clin Appl Thromb Hemost. 2004;  10 277-280
• 60 Johnson R M, Barbarini G, Barbaro G. Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients.  AIDS. 2003;  17(suppl 1) S77-S82
• 61 Connor M D, Lammie G A, Bell J E et al.. Cerebral infarction in adult AIDS patients: observation from the Edinburgh HIV Autopsy Cohort.  Stroke. 2000;  31 2117-2126
• 62 Trotti R, Rondanelli M, Anesi A, Gabanti E, Brustia R, Minoli L. Increased erythrocyte glutathione peroxidase activity and serum tumor necrosis factor-α in HIV-infected patients: relationship to on-going prothrombotic state.  J Hematother Stem Cell Res. 2002;  11 369-375
• 63 Schecter A D, Berman A B, Yi L et al.. HIV envelope gp120 activates human arterial smooth muscle cells.  Proc Natl Acad Sci USA. 2001;  98 10142-10147
• 64 Saif M W, Greenberg B. HIV and thrombosis: a review.  AIDS Patient Care STDS. 2001;  15 15-24
• 65 Hoffmann M, Berger J R, Nath A, Rayens M. Cerebrovascular disease in young, HIV-infected black Africans in the KwaZulu Natal Province of South Africa.  J Neurovirol. 2000;  6 229-236
• 66 Chetty R. Vasculitides associated with HIV infection.  J Clin Pathol. 2001;  54 275-278
• 67 Noel B. Vascular complications of cocaine use.  Stroke. 2002;  33 1747-1748
• 68 Wu D T, Woodman S E, Weiss J M et al.. Mechanisms of leukocyte trafficking into the CNS.  J Neurovirol. 2000;  6 S82-S85
• 69 Brilla R, Nabavi D G, Schulte-Atedorneburg G et al.. Cerebral vasculopathy in HIV infection revealed by transcranial doppler: a pilot study.  Stroke. 1999;  30 811-813
• 70 Lee G A, Seneviratne T, Noor M A et al.. The metabolic effects of lopinavir/ritonavir in HIV-negative men.  AIDS. 2004;  18 641-649
• 71 Copur A S, Smith P R, Gomez V, Bergman M, Homel P. HIV infection is a risk factor for venous thromboembolism.  AIDS Patient Care STDS. 2002;  16 205-209
• 72 Wanke C A, Falutz J M, Shevitz A, Phair J P, Kotler D P. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.  Clin Infect Dis. 2002;  34 248-259
• 73 Dressman J, Kincer J, Matveev S V et al.. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesterol ester accumulation in macrophages.  J Clin Invest. 2003;  111 389-397
• 74 Hui D Y. HIV protease inhibitors and atherosclerosis.  J Clin Invest. 2003;  111 317-318
• 75 Ninomiya J K, L’Italien G, Criqui M H et al.. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.  Circulation. 2004;  109 42-46
• 76 Williams R C. Periodontal disease.  N Engl J Med. 1990;  322 373-382
• 77 Brown L J, Brunelle J A, Kingman A. Periodontal status in the United States, 1988-1991: prevalence, extent, and demographic variation.  J Dent Res. 1996;  75 672-683
• 78 Silver J G, Martin A W, McBride B C. Experimental transient bacteremias in human subjects with varying degrees of plaque accumulation and gingival inflammation.  J Clin Periodontol. 1977;  4 92-99
• 79 Engebretson S P, Lamster I B, Elkind MSV et al.. Radiographic measures of periodontal disease and carotid atherosclerosis.  Stroke. 2005;  36 561-566
• 80 Beck J, Garcia R, Heiss G, Vokonas P S, Offenbacher S. Periodontal disease and cardiovascular disease.  J Periodontol. 1996;  67 1123-1137
• 81 Wu T, Trevisan M, Genco R J, Dorn J P, Falkner K L, Sempos C T. Periodontal disease and risk of cerebrovascular disease: the first National Health and Nutrition Examination Survey and its follow-up study.  Arch Intern Med. 2000;  160 2749-2755
• 82 Hujoel P P, Drangsholt M, Spiekerman C, DeRouen T A. Periodontal disease and coronary heart disease risk.  JAMA. 2000;  284 1406-1410
• 83 Veldhuyzen van Zanten S J, Sherman P M. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.  CMAJ. 1994;  150 177-185
• 84 Koenig W, Rothenbacher D, Hoffmeister A et al.. Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease.  Circulation. 1999;  100 2326-2331
• 85 Pasceri V, Cammarota G, Patti G et al.. Association of virulent Helicobacter pylori strains with ischemic heart disease.  Circulation. 1998;  97 1675-1679
• 86 Ameriso S F, Fridman E A, Leiguarda R C, Sevlever G E. Detection of Helicobacter pylori in human carotid atherosclerotic plaques.  Stroke. 2001;  32 385-391
• 87 Blasi F, Denti F, Erba M et al.. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms.  J Clin Microbiol. 1996;  34 2766-2769
• 88 Moazed T C, Kuo C, Grayston J T, Campbell L A. Murine models of Chlamydia pneumoniae infection and atherosclerosis.  J Infect Dis. 1997;  175 883-890
• 89 Laitinen K, Laurila A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.  Infect Immun. 1997;  65 4832-4835
• 90 Muhlestein J B, Anderson J L, Hammond E H et al.. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model.  Circulation. 1998;  97 633-636
• 91 Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS Study.  Eur Heart J. 1999;  20 121-127
• 92 Sander D, Winbeck K, Klingelhöfer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and C. pneumoniae seropositivity.  Circulation. 2002;  106 2428-2433
• 93 Sander D, Winbeck K, Klingelhöfer J et al.. Reduced progression of early carotid atherosclerosis after antibiotic treatment and C. pneumoniae seropositivity.  Circulation. 2002;  106 2428-2433
• 94 Sander D, Winbeck K, Klingelhöfer J et al.. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity.  Circulation. 2004;  109 1010-1015
• 95 O'Connor C M, Dunne M W, Pfeffer M A et al.. Azithromycin for the secondary prevention of coronary heart disease events-the WIZARD study: a randomized controlled trial.  JAMA. 2003;  290 1459-1466
• 96 Grayston J T, Kronmal R A, Jackson L A et al.. Azithromycin for the secondary prevention of coronary events.  N Engl J Med. 2005;  352 1637-1645
• 97 Cannon C P, Braunwald E, McCabe C H et al.. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.  N Engl J Med. 2005;  352 1646-1654
• 98 Prospective Studies Collaboration . Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts.  Lancet. 1995;  346 1647-1653
• 99 Espinola-Klein C, Rupprecht H J, Blankenberg S et al.. Impact of infectious burden on extent and long-term prognosis of atherosclerosis.  Circulation. 2002;  105 15-21
• 100 Espinola-Klein C, Rupprecht H J, Blankenberg S et al.. Impact of infectious burden on progression of carotid atherosclerosis.  Stroke. 2002;  33 2581-2586
• 101 Smieja M, Gnarpe J, Lonn E et al.. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.  Circulation. 2003;  107 251-257
• 102 Ezekowitz R A. Genetic heterogeneity of mannose-binding proteins: the Jekyll and Hyde of innate immunity?.  Am J Hum Genet. 1998;  62 6-9
• 103 Hegele R A, Ban M R, Anderson C M, Spence J D. Infection-susceptibility alleles of mannose-binding lectin are associated with increased carotid plaque area.  J Investig Med. 2000;  48 198-202
• 104 Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. Effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection.  J Am Coll Cardiol. 2001;  38 712-717